Exchange & Returns Information
Review Details
(0)
| Generic For | AVASTIN |
|---|---|
| Active Ingredient | BEVACIZUMAB |
| Strength | 400MG |
| Manufacturer | HETERO DRUGS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 110.00 | $ 110.00 |
$ 93.50
Apply ZARVY26 (-15%)
You save $ 16.50
|
||
| 2 BOXES - 2 VIALS | $ 114.00 | $ 228.00 |
$ 193.80
Apply ZARVY26 (-15%)
You save $ 34.20
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 115.33 | $ 346.00 |
$ 294.10
Apply ZARVY26 (-15%)
You save $ 51.90
|
Reference information will be available soon.
Cizumab 400 is a 400mg/16ml injectable formulation of bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF-A. It inhibits angiogenesis by preventing VEGF from binding to its receptors on endothelial cells, thus limiting blood supply to tumors. Cizumab 400 is used in multiple solid tumors including colorectal, lung, ovarian, brain, cervical, renal, and liver cancers. This higher-dose vial is suitable for body-weight-based regimens that require larger volumes, reducing preparation time and vial burden.
AntiCancer Drugs > Colorectal Cancer
Used in combination with chemotherapy regimens such as FOLFOX, FOLFIRI, and CAPEOX in both first-line and second-line settings for metastatic colorectal cancer. Enhances chemotherapy delivery and improves survival outcomes.
Non-Small Cell Lung Cancer (non-squamous)
Administered with platinum-doublet chemotherapy in patients with advanced or unresectable non-squamous NSCLC. Demonstrates benefit even in patients with brain metastases.
Glioblastoma
Indicated for recurrent glioblastoma, particularly in patients with steroid-refractory cerebral edema. Helps relieve intracranial pressure and stabilize disease progression.
Renal Cell Carcinoma
Used in combination with interferon-alpha in metastatic clear cell RCC to inhibit tumor vascularization and improve progression-free survival.
Cervical Cancer
Used with paclitaxel and either cisplatin or topotecan in persistent, recurrent, or metastatic cervical cancer. Clinical trials confirm survival benefit when included in combination regimens.
Ovarian, Fallopian, and Peritoneal Cancers
Approved for use in newly diagnosed and recurrent epithelial ovarian cancers, both platinum-sensitive and platinum-resistant. Also indicated as maintenance therapy following chemotherapy response.
Hepatocellular Carcinoma
Combined with atezolizumab in first-line treatment for advanced or unresectable HCC. This regimen is recognized as a new standard of care globally.
Colorectal Cancer
5 mg/kg IV q2w with IFL
10 mg/kg IV q2w with FOLFOX4
5–7.5 mg/kg IV q2–3w as second-line
NSCLC (non-squamous)
15 mg/kg IV q3w with carboplatin + paclitaxel
Glioblastoma
10 mg/kg IV q2w for recurrent disease
Renal Cell Carcinoma
10 mg/kg IV q2w with interferon-alpha
Cervical Cancer
15 mg/kg IV q3w with paclitaxel + cisplatin/topotecan
Ovarian, Fallopian, Peritoneal Cancer
15 mg/kg IV q3w ×6 cycles (initial)
Maintenance: 15 mg/kg IV q3w for up to 22 cycles
Recurrent (Platinum-resistant): 10–15 mg/kg IV q2–3w with topotecan, PLD, or weekly paclitaxel
Recurrent (Platinum-sensitive): 15 mg/kg IV q3w with carboplatin + paclitaxel or gemcitabine
Hepatocellular Carcinoma
15 mg/kg IV q3w following 1200 mg IV atezolizumab
Admin Instructions:
1st infusion: 90 min → 2nd: 60 min → subsequent: 30 min if well tolerated
Continue until disease progression or unacceptable toxicity
Store in a refrigerator (2°C–8°C). Do not freeze or shake. Protect from light and use aseptic technique. Discard unused solution after opening.
Common side effects: hypertension, proteinuria, fatigue, epistaxis Serious adverse effects: gastrointestinal perforation, arterial thromboembolism, hemorrhage, delayed wound healing Rare: RPLS (Reversible Posterior Leukoencephalopathy Syndrome), fistula formation Monitoring: blood pressure, urine protein, CBC, surgical history assessment
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
